Below is the current list of studies covered by the CIRB. It includes both Available to Open and Completed studies. Study documents approved after July 1, 2013 for all covered studies are available on the CTSU website.
To request documents approved before July 1, 2013, please contact the CIRB Helpdesk.
|Study Number||Lead Group||Study Title||CIRB||Study Status|
|CALGB-30610||CALGB||Phase III Comparison of Thoracic Radiotherapy Regimens in Patients with Limited Small Cell Lung Cancer also Receiving Cisplatin or Carboplatin and Etoposide||Adult CIRB - Late Phase Emphasis||Available to Open|
|AAML0531||COG||A Phase III Randomized Trial of Gemtuzumab Ozogamicin (Mylotarg) Combined with Conventional Chemotherapy for De Novo Acute Myeloid Leukemia (AML) in Children; Adolescents; and Young Adults||Pediatric CIRB||Available to Open|
|RTOG-1216||RTOG||Randomized Phase II/III Trial of Surgery and Postoperative Radiation Delivered with Concurrent Cisplatin versus Docetaxel versus Docetaxel and Cetuximab for High-Risk Squamous Cell Cancer of the Head and Neck||Adult CIRB - Late Phase Emphasis||Available to Open|
|S1607||SWOG||A Phase II Study of Combining Talimogene Laherparepvec (T-VEC) (NSC-785349) and MK-3475 (Pembrolizumab) (NSC-776864) in Patients with Advanced Melanoma who have Progressed on ANTI-PD1/L1 Based Therapy||Adult CIRB - Late Phase Emphasis||Available to Open|
|EAE161||ECOG-ACRIN||Perfusion CT to Predict Progression-free Survival and Response Rate in Bevacizumab and Paclitaxel Treatment of Platinum-Resistant Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Peritoneal Carcinoma||Adult CIRB - Late Phase Emphasis||Available to Open|
|A031803||Alliance||Phase II Trial of Intravesical Gemcitabine and MK-3475 (pembrolizumab) in the Treatment of Patients with BCG-Unresponsive Non-Muscle Invasive Bladder Cancer||Adult CIRB - Late Phase Emphasis||Available to Open|
|10217||ETCTN||A Phase 1b Biomarker-Driven Combination Trial of Copanlisib, Olaparib, and MEDI4736 (Durvalumab) in Patients with Advanced Solid Tumors||Adult CIRB - Early Phase Emphasis||Available to Open|
|E1105||ECOG||A Randomized Phase III Double-Blind Placebo-Controlled Trial of First-line Chemotherapy and Trastuzumab with or without Bevacizumab for Patients with HER-2/NEU Over-expressing Metastatic Breast Cancer||Adult CIRB - Late Phase Emphasis||Available to Open|
|ADVL0221||COG||A Phase II Study of Trabectedin (ET-743; Yondelis) in Children with Recurrent Rhabdomyosarcoma; Ewing Sarcoma; or Nonrhabdomyosarcomatous Soft Tissue Sarcomas||Pediatric CIRB||Completed|
|E3999||ECOG||A Randomized; Placebo-controlled; Double Blind; Trial of the Administration of the MDR Modulator; Zosuquidar Trihydrochloride (LY335979); During Conventional Induction and Post-Remission Therapy in Patients Greater than 60 Years of Age with Newly Diagnosed Acute Myeloid Leukemia; Refractory Anemia with Excess Blasts in Transformation or High-Risk Refractory Anemia with Excess Blasts||Adult CIRB - Late Phase Emphasis||Completed|